Construction and in vitro study of eukaryotic expression vector carrying GITRL and IL-21 gene.
10.7534/j.issn.1009-2137.2014.05.021
- Author:
Bin XIONG
1
;
Ming-Xia ZHU
1
;
Qi-Mei JIN
1
;
Fei-Xue SONG
2
Author Information
1. Department of Oncology, The Second Hospital of Lanzhou University, Lanzhou 73003, Gansu Province, China.
2. Department of Oncology, The Second Hospital of Lanzhou University, Lanzhou 73003, Gansu Province, China. E-mail: 13639336037@139.com.
- Publication Type:Journal Article
- MeSH:
Cytokine-Induced Killer Cells;
Dendritic Cells;
Humans;
In Vitro Techniques;
Interferon-gamma;
Interleukin-2;
Interleukins;
genetics;
Transfection;
Tumor Necrosis Factors;
genetics
- From:
Journal of Experimental Hematology
2014;22(5):1295-1300
- CountryChina
- Language:Chinese
-
Abstract:
The aim of this study was to construct the eukaryotic expression vector carrying glucocorticoid-induced tumor necrosis factor receptor ligand (GITRL) and interleukin-21 (IL-21) gene for transfection into chronic myeloid leukemia (CML) dervied dendritic cell (DC), so as to provide an effective platform for exploring the function of target gene in CML. The recombinant eukaryotic expression vector was transfected to the purified DC by Liposome-mediated method, the interleukin-2 (IL-2) and Interferon-γ (IFN-γ) expression of transfected DC were analyzed by ELISA. Further, the transfected DC with purified NK were mixed and cultured to be DC-CIK, the lactate dehydrogenase release assay was performed to measure the killing activity of DC-CIK. The results indicated that the sequence of cloned target gene was same as that in GenBank. The size of endonuclease products by restriction enzyme were same as the predict one. The concentration of Interleukin-2 (IL-2) and interferon-γ (IFN-γ) in transfected DC all increased. The NK kill activity became stronger while induced by transfected DC. It is concluded that DC transfected by IL-21 and GITRL gene has the ability of self-activation, up-regulate cytokine secretion. Further, the results would be help to provide the theoretical evidence of advanced immunotherapy for treatment of CML patients who showed no reaction to tyrosine kinase inhibitor.
